Publication
Follistatin drives AR-independent prostate cancer through BMP signaling inactivation and microenvironmental remodeling.
Xiaoxian Shi, Zuyan Fan, Min Qu, Chunjie Lin, Zhiheng Ji, Caiwei Tan, Biqi Dai, Rushan Chen, Yixuan Du, Yizhong Bao, Zhifan Ding, Liqun Xia, Furong Liu, Hongliang Gao, Tianyu Cao, Wei Xie, Dong Fang, Weijie Zhang, Deli Huang, Jun Chen, Xu Gao, Xinhua Feng, Gonghui Li, Jing Li, Wenjing Su
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Resistance to androgen receptor (AR)-targeted therapies remains a major clinical challenge in advanced prostate cancer. Here we identify follistatin (FST), TGFβ superfamily antagonist, as a key driver of AR-independence and treatment resistance. During anti-AR therapy, cancer cells progressively…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available